Nasdaq

Barinthus Biotherapeutics plc Announces Strategic Transformation and Advancements in Immunology Pipeline, Including Celiac Disease Therapy VTP-1000

Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease, which ...
Yahoo Finance

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

OXFORD, United Kingdom, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that ...
manilatimes

ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)

- Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP - TEL AVIV, Israel, June 05, 2025 ...
Seeking Alpha

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease. An estimated one in 100 people globally suffer from celiac disease, for which ...
Seeking Alpha

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no ...